Pembrolizumab: tested on its own

368 studies: no other medicine in its arm. Page 3 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)CompletedNCT02447003Phase 2Results postedReport a problem
• Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02444741Phase 1/2Results postedReport a problem
• Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer PatientsCompletedNCT02437071Phase 2Results postedReport a problem
• A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced MelanomaCompletedNCT02434354Phase 1Results postedReport a problem
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results postedReport a problem
• Pembrolizumab in Treating Patients With Malignant MesotheliomaCompletedNCT02399371Phase 2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)CompletedNCT02370498Phase 3Results postedReport a problem
• Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Active, not recruitingNCT02362594Phase 3Results postedReport a problem
• Pembrolizumab in Treating Patients With Advanced Uveal MelanomaTerminatedNCT02359851Phase 2Results postedReport a problem
• MK-3475 as Maintenance Therapy in Extensive Stage SCLCCompletedNCT02359019Phase 2Results postedReport a problem
• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLCCompletedNCT02343952Phase 2Results postedReport a problem
• Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)CompletedNCT02335424Phase 2Results postedReport a problem
• Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung CancerCompletedNCT02316002Phase 2Results postedReport a problem
• MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant GliomasCompletedNCT02311582Phase 1/2Results postedReport a problem
• Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV MelanomaCompletedNCT02306850Phase 2Results postedReport a problem
• RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic CancersCompletedNCT02303990Phase 1Results postedReport a problem
• SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasCompletedNCT02301039Phase 2Results postedReport a problem
• Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and NeckCompletedNCT02289209Phase 2Results postedReport a problem
• Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerCompletedNCT02267603Phase 2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)CompletedNCT02256436Phase 3Results postedReport a problem
• Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)CompletedNCT02255097Phase 2Results postedReport a problem
• Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)CompletedNCT02252042Phase 3Results postedReport a problem
• Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary SyndromeCompletedNCT02243579Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)CompletedNCT02220894Phase 3Results postedReport a problem
• A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)TerminatedNCT02212730Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)CompletedNCT02180061Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)CompletedNCT02142738Phase 3Results postedReport a problem
• Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerCompletedNCT02129556Phase 1/2Results postedReport a problem
• MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesCompletedNCT02085070Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)CompletedNCT02054806Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)CompletedNCT02007070Phase 1Results postedReport a problem
• Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)CompletedNCT01905657Phase 2/3Results postedReport a problem
• Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)CompletedNCT01876511Phase 2Results postedReport a problem
• Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)CompletedNCT01848834Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results postedReport a problem
• Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)WithdrawnNCT07513324Phase 2Report a problem
• Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)Active, not recruitingNCT07376317Phase 2Report a problem
• A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer ParticipantsActive, not recruitingNCT07180862Phase 1Report a problem
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3Report a problem
• Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT06580054Phase 2Report a problem
• Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic CancerCompletedNCT06378047Phase 1Report a problem
• A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT06348199Phase 3Report a problem
• Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3Report a problem
• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1Report a problem
• A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyActive, not recruitingNCT06268613Phase 1Report a problem
• Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine CancerActive, not recruitingNCT06180733Phase 2Report a problem
• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3Report a problem
• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1Report a problem
• A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)WithdrawnNCT06050954Phase 2Report a problem
• Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)TerminatedNCT06005818Phase 2Report a problem
• Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3Report a problem
• Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept StudyStatus unknownNCT05761132Phase 2Report a problem
• Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1Report a problem
• Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell CarcinomaActive, not recruitingNCT05737199Phase 2Report a problem
• Response to Immunotherapy in MMR-deficient Localized Colon CancerCompletedNCT05662527Phase 2Report a problem
• Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDStatus unknownNCT05578222Phase 2Report a problem
• Induction Immunochemotherapy in Stage III-IVa Head and Neck CancerStatus unknownNCT05551767Phase 2Report a problem
• Pembrolizumab Plus CRT Followed by Surgery in Upper ESCCStatus unknownNCT05541445Phase 1/2Report a problem
• Immunotherapy Combined With Radiotherapy for Metastatic SarcomaActive, not recruitingNCT05488366Early Phase 1Report a problem
• Pembrolizumab in Muscle-invasive Bladder CancerActive, not recruitingNCT05406713Phase 2Report a problem
• Neoadjuvant/Adjuvant Pembrolizumab Plus ChemotherapyActive, not recruitingNCT05383716Phase 2Report a problem
• Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicableReport a problem
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active, not recruitingNCT05239741Phase 3Report a problem
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1Report a problem
• Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2Report a problem
• NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal CancerActive, not recruitingNCT05197322Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)Active, not recruitingNCT05173987Phase 3Report a problem
• Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal CancersActive, not recruitingNCT05131919Phase 2Report a problem
• A Study of Pembrolizumab and Cryoablation in People With MesotheliomaCompletedNCT05071014Phase 1Report a problem
• Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)Active, not recruitingNCT04938609Phase 2Report a problem
• Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )Status unknownNCT04863079Phase 2Report a problem
• RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyCompletedNCT04827862Phase 2Report a problem
• Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ AdenocarcinomaStatus unknownNCT04813523Phase 2Report a problem
• Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.Active, not recruitingNCT04795661Phase 2Report a problem
• Pembrolizumab for the Treatment of Cervical Intraepithelial NeoplasiaActive, not recruitingNCT04712851Phase 2Report a problem
• FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid TumorsStatus unknownNCT04699643Phase 1/2Report a problem
• Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent MeningiomaActive, not recruitingNCT04659811Phase 2Report a problem
• Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2Report a problem
• Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)WithdrawnNCT04569461Phase 2Report a problem
• Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer PatientsWithdrawnNCT04565496Phase 2Report a problem
• BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade TherapyActive, not recruitingNCT04454528Phase 1/2Report a problem
• Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT04435197Phase 2Report a problem
• Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaActive, not recruitingNCT04417166Phase 2Report a problem
• Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Phase 2Report a problem
• Study of Dara-Pembro for Multiple Myeloma PatientsWithdrawnNCT04361851Phase 2Report a problem
• Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCCActive, not recruitingNCT04340258Phase 1/2Report a problem
• Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&NCompletedNCT04323202Phase 1Report a problem
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaSuspendedNCT04318717Phase 2Report a problem
• Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)Status unknownNCT04303884Phase 2Report a problem
• Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility StudyCompletedNCT04262089Phase 1Report a problem
• A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTEWithdrawnNCT04258683Phase 2Report a problem
• Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 PositiveActive, not recruitingNCT04249739Phase 2Report a problem
• Pembrolizumab in Early Stage Colon CancerWithdrawnNCT04231526Phase 2Report a problem
• Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT04227509Phase 2Report a problem
• Longitudinal Immune-phenotyping of HCC Following MK-3475Active, not recruitingNCT04224480Phase 1Report a problem
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3Report a problem
• Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical LesionsStatus unknownNCT04211103Phase 2Report a problem

← Pembrolizumab